International Journal of Surgery

Marizyme CEO Delivers Business Update

Retrieved on: 
Wednesday, May 3, 2023
CABG, Intellectual property, Chronic kidney disease, Frontiers, ISO, Frontiers in Cardiovascular Medicine, International Journal of Surgery, Frequency, Quality, Sale, Certification, MDR, Publication, Canadian International Council, Cardiology, Quality of life, Form, Growth, United Kingdom, Diagnosis, FDA, Oxford University Press, European Journal, Asset management, Risk management, Medical device, Pharmaceutical industry, Tobacco, Cryptocurrency, EU, European, Patient

JUPITER, FL, May 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel.

Key Points: 
  • JUPITER, FL, May 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel.
  • I am pleased to bring you an update on the Company’s recent developments as well as Marizyme’s current business priorities and goals.
  • The Company’s primary business priority continues to be working with the FDA where DuraGraft® is currently under review for authorization in the United States.
  • Completed regulatory and manufacturing transition to produce “Marizyme” labeled DuraGraft® products for sale in the EU and certain other markets.

Channel Medsystems Announces Publication of Long-term Clinical Outcomes with Cerene® Cryotherapy for the Treatment of Heavy Menstrual Bleeding

Retrieved on: 
Wednesday, August 10, 2022
Women, Surgery, General Health, Health, Medical Devices, Health Technology, Consumer, Clinical Trials, Woman, International Journal of Surgery, Microdeletion syndrome, CLARITY, Trial of the century, Endometrium, CA, Incidence, Pain, HMB, Quality of life, Channel, Patient, Vanderbilt University Medical Center, Gynaecology, Safety, Treatment, Manuscript, Canadian International Council, Physician, Journal, Cryotherapy, LinkedIn, Birth control, Health insurance, Omri Ceren

The manuscript, entitled The Cerene Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding: 36-Month Outcomes from The CLARITY Study, is available on the International Journal of Womens Health website .

Key Points: 
  • The manuscript, entitled The Cerene Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding: 36-Month Outcomes from The CLARITY Study, is available on the International Journal of Womens Health website .
  • The CLARITY study was a prospective, multi-center, single-arm, open-label study that evaluated 242 premenopausal women who underwent cryoablation with Cerene.
  • At 36 months, 85% of patients were satisfied or very satisfied and 91% would definitely or maybe recommend Cerene.
  • Cerene is an in-office endometrial cryoablation treatment that safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia.

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Retrieved on: 
Tuesday, April 19, 2022
Research, Technology, Other Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, EMA, CEO, Nature, IPO, Twitter, Software, Insight, Bias, Synthetic control method, International Journal of Surgery, RCT, Merck Group, European Medicines Agency, Â, Machine learning, Probability, Patient, II, III, LinkedIn, Efficiency, Scientific Reports, Technology, The International Journal of Biostatistics, Scale, Digital, AI, Randomized controlled trial, Venture round, Investment, 2021 Essex County Council election, Insight Partners, Financial services, Pharmaceutical industry, Biostatistics, Youngblood Brass Band

Unlearn, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that it has closed a $50 million Series B funding round.

Key Points: 
  • Unlearn, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that it has closed a $50 million Series B funding round.
  • Unlearn works with pharma sponsors, biotech companies, and academic institutions to optimize human clinical trials with TwinRCTs.
  • We are excited to support the Unlearn team as they scale their TwinRCT solution to make clinical trials better for patients and for sponsors.
  • Unlearn.AI is the only company creating TwinRCTs, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials.